Research Advances of Novel Coronavirus Disease (COVID-19)

doi:10.13523/j.cb.2002103

China Biotechnology

2020, Vol. 40

Issue (1-2): 38-50 DOI: 10.13523/j.cb.2002103

Orginal Article

Research Advances of Novel Coronavirus Disease (COVID-19)

ZHU Xiao-li^1,^*(

),HUANG Cui¹,MA Li-li¹,ZHANG Chao²,GONG Yue²,ZHAO Wan-yu²,ZHAO Xiu-fang²,GUO Wen-jiao²,PENG Hao²,ZHANG Ji¹,LIANG Hui-gang¹

1 Wuhan Library, Chinese Academy of Science, Wuhan 430071, China
2 National Science Library, Chinese Academy of Sciences, Beijing 100190, China

Download:

HTML

PDF(760KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

In December 2019, Wuhan, Hubei Province, an outbreak of pneumonia caused by a novel coronavirus (COVID-19) subsequently spread to all provinces and areas in China and many countries, that was declared as a Public Health Emergency of International Concern (PHEIC) by WHO. It is important to understand and characterize the virus timely to fight with the epidemic. The papers on COVID-19 by the researchers from various fields around the world within two months after the outbreak were studied and found that these studies mainly focused on traceability analysis, detection methods, patient treatment, clinical manifestations, drug development, pathogenic mechanisms, transmission ways, epidemic characteristics. The coronavirus is closely related to bat coronavirus and pangolin coronavirus. It has the same human receptor ACE2 as SARS-CoV, and the infection pathway is confirmed to be the respiratory and digestive systems. The virus indicates person-to-person and asymptomatic transmission. Most of the confirmed cases of COVID-19 are related to Wuhan, and most cases are mild, the elderly have a higher mortality rate. Rapid and sensitive nucleic acid testing is usually used as a basis for diagnosis. Currently, valuable drug candidates such as remdesivir have been screened for clinical trials. Intervention measures such as travel bans and quarantine adopted have effectively reduced the spread of the epidemic.

Key words： COVID-19 Epidemic characteristics Clinical manifestations Drug development Pathogenic mechanism

Received: 24 February 2020 Published: 27 March 2020

ZTFLH:

Q819

Corresponding Authors: Xiao-li ZHU E-mail: zxl_8709@163.com

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Xiao-li ZHU
	Cui HUANG
	Li-li MA
	Chao ZHANG
	Yue GONG
	Wan-yu ZHAO
	Xiu-fang ZHAO
	Wen-jiao GUO
	Hao PENG
	Ji ZHANG
	Hui-gang LIANG

Cite this article:

ZHU Xiao-li,HUANG Cui,MA Li-li,ZHANG Chao,GONG Yue,ZHAO Wan-yu,ZHAO Xiu-fang,GUO Wen-jiao,PENG Hao,ZHANG Ji,LIANG Hui-gang. Research Advances of Novel Coronavirus Disease (COVID-19). China Biotechnology, 2020, 40(1-2): 38-50.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.2002103 OR https://manu60.magtech.com.cn/biotech/Y2020/V40/I1-2/38

Fig.1 research fields of academic papers posted before February 11, 2020


[1]	Nature. Coronavirus disease officially named COVID-19.[2020-02-12]. https://www.nature.com/articles/d41586-020-00154-w.

[2]	WHO. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). [2020-01-31]. https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)

[3]	WHO. Coronavirus disease 2019 (COVID-19) Situation Report - 33. [2020-02-23]. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200222-sitrep-33-covid-19.pdf?sfvrsn=c9585c8f_2.

[4]	Elisabeth Mahase. China coronavirus: WHO declares international emergency as death toll exceeds 200. [2020-02-01]. https://www.bmj.com/content/368/bmj.m408.

[5]	The Lancet. COVID-19 Resource Centre. [2020-02-23]. https://www.thelancet.com/coronavirus.

[6]	The New England Journal of Medicine. Coronavirus (Covid-19).[2020-02-23]. https://www.nejm.org/coronavirus?query=main_nav_lg.

[7]	JAMA. Coronavirus Disease 2019 (COVID-19). [2020-02-23]. https://jamanetwork.com/journals/jama/pages/coronavirus-alert.

[8]	British Medical Journal. Coronavirus: Latest news and resources. [2020-02-23]. https://www.bmj.com/coronavirus.

[9]	Nature. SARS-CoV-2 and COVID-19: A new virus and associated respiratory disease. [2020-02-23]. https://www.springernature.com/gp/researchers/campaigns/coronavirus.

[10]	US CDC. This guidance provides clarification regarding evaluation for home isolation and a new section with information regarding preventative steps for household members, intimate partners, and caregivers in a nonhealthcare setting of a person with symptomatic, laboratory-confirmed COVID-19. [2020-01-24] https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-prevent-spread.html.

[11]	Del Rio C, Malani P N . 2019 Novel Coronavirus-Important Information for Clinicians. JAMA. [2020-02-05]. doi: 10.1001/jama.2020.1490. doi: 10.1001/jama.2020.1490

[12]	Dong N, Yang X M, Ye L W , et al. Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. BioRxiv. [2020-01-22]. doi: https://doi.org/10.1101/2020.01.20.913368. doi: https://doi.org/10.1101/2020.01.20.913368

[13]	陈嘉源, 施劲松, 丘栋安 , 等. 2019新型冠状病毒基因组的生物信息学分析. 生物信息学. [2020-02-26]. http://kns.cnki.net/kcms/detail/23.1513.q.20200120.0839.002.html.

[13]	Chen J Y, Shi J S, Qiu D A , et al. Genomic bioinformatics analysis of the novel coronavirus (2019-nCoV) Bioinformatics. [2020-02-26]. http://kns.cnki.net/kcms/detail/23.1513.q.20200120.0839.002.html.

[14]	Zhou P, Yang X L, Wang X G , et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature.[2020-02-03]. doi: 10.1038/s41586-020-2012-7. doi: 10.1038/s41586-020-2012-7

[15]	Zhu H Q, Guo Q, Li M , et al. Host and infectivity prediction of Wuhan 2019 novel coronavirus using deep learning algorithm. bioRxiv. [2020-01-24]. doi: https://doi.org/10.1101/2020.01.21.914044. doi: https://doi.org/10.1101/2020.01.21.914044

[16]	Wu F, Zhao S, Yu B , et al. Complete genome characterization of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. bioRxiv.[2020-01-25]. doi: https://doi.org/10.1101/2020.01.24.919183. doi: https://doi.org/10.1101/2020.01.24.919183

[17]	Gurjit S R, Maximillian P.M. S, Hadi El R , et al. Machine learning-based analysis of genomes suggests associations between Wuhan 2019-nCoV and bat Betacoronaviruses. bioRxiv. [2020-02-04]. doi: https://doi.org/10.1101/2020.02.03.932350. doi: https://doi.org/10.1101/2020.02.03.932350

[18]	WHO. Novel Coronavirus(2019-nCoV) Situation Report - 22. [2020-02-11] https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2.

[19]	Ren L L, Wang Y M, Wu Z Q , et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J. 2020, 133: Epub ahead of print. DOI: 10.3760/cma.j.issn.0366-6999.2020.00.E001. doi: 10.3760/cma.j.issn.0366-6999.2020.00.E001

[20]	Ji W, Wang W, Zhao X , et al. Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol. 2020,92(4):433-440. doi: 10.1002/jmv.25682. doi: 10.1002/jmv.25682

[21]	David L Robertson . nCoV’s relationship to bat coronaviruses & recombination signals (no snakes) - no evidence the 2019-nCoV lineage is recombinant. [2020-01-23]. http://virological.org/t/ncovs-relationship-to-bat-coronaviruses-recombination-signals-no-snakes/331.

[22]	Todd Castoe . nCoV-2019 codon usage and reservoir (not snakes v2).[2020-01-29]. http://virological.org/t/ncov-2019-codon-usage-and-reservoir-not-snakes-v2/339/3.

[23]	Zhang C X, Zheng W, Huang X Q , et al. Protein structure and sequence re-analysis of 2019-nCoV genome does not indicate snakes as its intermediate host or the unique similarity between its spike protein insertions and HIV-1. bioRxiv. [2020-02-08]. doi: https://doi.org/10.1101/2020.02.04.933135. doi: https://doi.org/10.1101/2020.02.04.933135

[24]	David Cyranoski . “Did pangolins spread the China coronavirus to people?”[2020-02-08]. https://www.nature.com/articles/d41586-020-00364-2.

[25]	Xiao K P, Zhai J Q, Feng Y Y , et al. solation and Characterization of 2019-nCoV-like Coronavirus from Malayan Pangolins. bioRxiv. [2020-02-20]. doi: https://doi.org/10.1101/2020.02.17.951335. doi: https://doi.org/10.1101/2020.02.17.951335

[26]	Wong M C, Javornik Cregeen S J, Ajami N J , et al. Evidence of recombination in coronaviruses implicating pangolin origins of nCoV-2019. bioRxiv. [2020-01-13]. doi: https://doi.org/10.1101/2020.02.07.939207. doi: https://doi.org/10.1101/2020.02.07.939207

[27]	Lam T-K T, Shum H-H M, Zhu H C , et al. Identification of 2019 -nCoV related coronaviruses in Malayan pangolins in southern China. bioRxiv. [2020-02-18]. doi: https://doi.org/10.1101/2020.02.13.945485. doi: https://doi.org/10.1101/2020.02.13.945485

[28]	Liu P, Jiang J Z, Wan X F , et al. Are pangolins the intermediate host of the 2019 novel coronavirus (2019-nCoV) ? bioRxiv. [2020-02-20]. doi: https://doi.org/10.1101/2020.02.18.954628. doi: https://doi.org/10.1101/2020.02.18.954628

[29]	Nature Ecology & Evolution. Prevent and predict. [2020-02-20]. https://doi.org/10.1038/s41559-020-1150-5.

[30]	Xu X T, Chen P C, Wang J F , et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Science China Life Sciences. [2020-01-21]. https://doi.org/10.1007/s11427-020-1637-5.

[31]	Lu R, Zhao X, Li J , et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020,395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. doi: 10.1016/S0140-6736(20)30251-8

[32]	Bao L L, Deng W, Huang B Y , et al. The Pathogenicity of 2019 Novel Coronavirus in hACE2 Transgenic Mice. bioRxiv. [2020-01-11]. doi: https://doi.org/10.1101/2020.02.07.939389. doi: https://doi.org/10.1101/2020.02.07.939389

[33]	Zhao Y, Zhao Z X, Wang Y J , et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv. [2020-01-26]. doi: https://doi.org/10.1101/2020.01.26.919985. doi: https://doi.org/10.1101/2020.01.26.919985

[34]	Zhang H, Kang Z J, Gong H Y , et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv. [2020-01-31]. doi: https://doi.org/10.1101/2020.01.30.927806. doi: https://doi.org/10.1101/2020.01.30.927806

[35]	Meng T, Cao H, Zhang Z J , et al. The insert sequence in SARS-CoV-2 enhances spike protein cleavage by TMPRSS. bioRxiv.[2020-02-16]. doi: https://doi.org/10.1101/2020.02.08.926006. doi: https://doi.org/10.1101/2020.02.08.926006

[36]	Wu C, Zheng S F, Chen Y , et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCoV, in the nasal tissue. medRxiv. [2020-02-18]. doi: https://doi.org/10.1101/2020.02.11.20022228. doi: https://doi.org/10.1101/2020.02.11.20022228

[37]	Chai X Q, Hu L F, Zhang Y , et al. Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019 -nCoV Infection. bioRxiv. [2020-02-04]. doi: https://doi.org/10.1101/2020.02.03.931766. doi: https://doi.org/10.1101/2020.02.03.931766

[38]	Chan JF, Kok KH, Zhu Z , et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020,9(1):221-236. doi: 10.1080/22221751.2020.1719902. doi: 10.1080/22221751.2020.1719902

[39]	Beal J, Mitchell T, Wyschogrod D , et al. Highly Distinguished Amino Acid Sequences of 2019 -nCoV (Wuhan Coronavirus). bioRxiv. [2020-02-02]. doi: https://doi.org/10.1101/2020.01.31.929497. doi: https://doi.org/10.1101/2020.01.31.929497

[40]	Qiu T Y, Mao T T, Wang Y , et al. Identification of potential cross-protective epitope between 2019-nCoV and SARS virus. Journal of Genetics and Fenomics. [2020-01-30]. https://doi.org/10.1016/j.jgg.2020.01.003.

[41]	Ramaiah A, Arumugaswami V . Insights into Cross-species Evolution of Novel Human Coronavirus 2019 -nCoV and Defining Immune Determinants for Vaccine Development. bioRxiv. [2020-01-30]. doi: https://doi.org/10.1101/2020.01.29.925867. doi: https://doi.org/10.1101/2020.01.29.925867

[42]	Hoffmann M, Kleine-Weber H, Krüger N , et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. [2020-01-31]. doi: https://doi.org/10.1101/2020.01.31.929042. doi: https://doi.org/10.1101/2020.01.31.929042

[43]	Lei C H, Fu W Y, Qian K W , et al. Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig. bioRxiv. [2020-02-02]. doi: https://doi.org/10.1101/2020.02.01.929976. doi: https://doi.org/10.1101/2020.02.01.929976

[44]	Baruah V, Bose S . Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. J Med Virol. [2020-02-05]. doi: 10.1002/jmv.25698. doi: 10.1002/jmv.25698

[45]	Shanker A, Alluri A, Bhanu D . Analysis of Whole Genome Sequences and Homology Modelling of a 3-C Like Peptidase and a Non-Structural Protein of the Novel Coronavirus COVID-19 Shows Protein Ligand Interaction with an Aza-Peptide and a Noncovalent Lead Inhibitor with Possible Antiviral Properties. ChemRxiv.[2020-02-14]. https://chemrxiv.org/articles/Analysis_of_Whole_Genome_Sequences_and_Homology_Modelling_of_a_3C_Like_Peptidase_and_a_Non-Structural_Protein_of_the_Novel_Coronavirus_COVID-19_Shows_Protein_Ligand_Interaction_with_an_Aza-Peptide_and_a_Noncovalent_Lead_Inhibitor_with_Possi/11846943/1.

[46]	Ahmed S F, Quadeer A A, McKay M R . Preliminary identification of potential vaccine targets for 2019-nCoV based on SARS-CoV immunological studies. bioRxiv. [2020-02-04]. doi: https://doi.org/10.1101/2020.02.03.933226. doi: https://doi.org/10.1101/2020.02.03.933226

[47]	Wrapp D, Wang N S, Corbert K S , et al. Cryo-EM Structure of the 2019 -nCoV Spike in the Prefusion Conformation. bioRxiv. [2020-02-15]. doi: https://doi.org/10.1101/2020.02.11.944462. doi: https://doi.org/10.1101/2020.02.11.944462

[48]	Meng T, Cao H, Zhang Z J , et al. The transmembrane serine protease inhibitors are potential antiviral drugs for 2019 -nCoV targeting the insertion sequence-induced viral infectivity enhancement. bioRxiv. [2020-02-11]. https://www.biorxiv.org/content/10.1101/2020.02.08.926006v1.article-info.

[49]	Drosten C . Researchers develop first diagnostic test for novel coronavirus in China. [2020-02-01]. https://www.charite.de/en/service/press_reports/artikel/detail/researchers_develop_first_diagnostic_test_for_novel_coronavirus_in_china/.

[50]	WHO. Molecular assays to diagnose 2019 -nCoV. [2020-02-01]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance.

[51]	Zhu N, Zhang D, Wang W , et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. doi: 10.1056/NEJMoa2001017. doi: 10.1056/NEJMoa2001017

[52]	Chu DKW, Pan Y, Cheng SMS , et al. Molecular Diagnosis of a Novel Coronavirus (2019 -nCoV) Causing an Outbreak of Pneumonia. Clin Chem [2020-01-31]. doi: 10.1093/clinchem/hvaa029. doi: 10.1093/clinchem/hvaa029

[53]	HKKUST. HKUST Research Team Invents World’s Fastest Coronavirus Detection Device Offering Diagnostic Results in 40 Minutes. [2020-02-07]. https://www.ust.hk/news/research-and-innovation/hkust-research-team-invents-worlds-fastest-coronavirus-detection.

[54]	Terence Lau Lokting. PolyU develops the world’s most comprehensive rapid, automated multiplex diagnostic system for detecting up to 40 infectious respiratory pathogens (including novel coronavirus) in a single test. [2020-02-11]. https://www.polyu.edu.hk/web/en/media/media_releases/index_id_6732.html.

[55]	El-Tholoth M, Bau H H, Song J Z . A Single and Two-Stage, Closed-Tube, Molecular Test for the 2019 Novel Coronavirus (COVID-19) at Home, Clinic, and Points of Entry. [2020-02-19]. https://chemrxiv.org/articles/A_Single_and_Two-Stage_Closed-Tube_Molecular_Test_for_the_2019_Novel_Coronavirus_COVID-19_at_Home_Clinic_and_Points_of_Entry/11860137.

[56]	To KK, Tsang OT, Chik-Yan Yip C , et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis. [2020-02-12]. doi: 10.1093/cid/ciaa149. doi: 10.1093/cid/ciaa149

[57]	Sheridan C . Coronavirus and the race to distribute reliable diagnostics. [2020-02-19]. https://www.nature.com/articles/d41587-020-00002-2.

[58]	Cohen J, Kupferschmidt K . Labs scramble to spot hidden coronavirus infections. [2020-02-11]. https://www.sciencemag.org/news/2020/02/labs-scramble-spot-hidden-coronavirus-infections.

[59]	Xiao SY, Wu Y, Liu H . Evolving status of the 2019 novel coronavirus infection: Proposal of conventional serologic assays for disease diagnosis and infection monitoring. J Med Virol. [2020-02-07]. doi: 10.1002/jmv.25702. doi: 10.1002/jmv.25702

[60]	Zhou M, Chen Y, Yang D X , et al. A Deep Learning Pipeline for Accurate Differential Diagnosis between Novel Coronavirus Pneumonia and Influenza Pneumonia. Preprints with The Lancet. [2020-02-19]. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3539663#.

[61]	Xie X Z, Zhong Z, Zhao W, et al. Chest CT for Typical 2019 -nCoV Pneumonia: Relationship to Negative RT-PCR Testing Radiology. [2020-02-12]. doi: 10.1148/radiol.2020200343. doi: 10.1148/radiol.2020200343

[62]	Ai J W, Zhang H C, Xu T , et al. Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in Eastern China. medRxiv.[2020-02-17]. doi: https://doi.org/10.1101/2020.02.13.20022673. doi: https://doi.org/10.1101/2020.02.13.20022673

[63]	Li G D, Clercp E D . Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery. [2020-02-10]. https://www.nature.com/articles/d41573-020-00016-0.

[64]	Xu Z J, Peng C, Shi Y L , et al. Nelfinavir was predicted to be a potential inhibitor of 2019 -nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. bioRxiv. [2020-01-28]. doi: https://doi.org/10.1101/2020.01.27.921627. doi: https://doi.org/10.1101/2020.01.27.921627

[65]	Liu X, Wang X J . Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines. bioRxiv. [2020-01-29]. doi: https://doi.org/10.1101/2020.01.29.924100. doi: https://doi.org/10.1101/2020.01.29.924100

[66]	Ju J Y, Kumar S, Li X X , et al. Nucleotide Analogues as Inhibitors of Viral Polymerases. bioRxiv.[2020-01-31]. doi: https://doi.org/10.1101/2020.01.30.927574. doi: https://doi.org/10.1101/2020.01.30.927574

[67]	Beck B R, Shin B, Choi Y , et al. Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019 -nCoV), Wuhan, China through a drug-target interaction deep learning model. bioRxiv. [2020-02-02]. doi: https://doi.org/10.1101/2020.01.31.929547. doi: https://doi.org/10.1101/2020.01.31.929547

[68]	Lin S, Shen R N . Molecular Modeling Evaluation of the Binding Abilities of Ritonavir and Lopinavir to Wuhan Pneumonia Coronavirus Proteases. bioRxiv. [2020-02-03]. doi: https://doi.org/10.1101/2020.01.31.929695. doi: https://doi.org/10.1101/2020.01.31.929695

[69]	Wang M, Cao R, Zhang L , et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019 -nCoV) in vitro. Cell Res. [2020-02-04]. https://doi.org/10.1038/s41422-020-0282-0.

[70]	Richardson P, Griffin I, Tucker C , et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020; 395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. doi: 10.1016/S0140-6736(20)30304-4

[71]	Cohen J . Can an anti-HIV combination or other existing drugs outwit the new coronavirus?. [2020-01-27].https://www.sciencemag.org/news/2020/01/can-anti-hiv-combination-or-other-existing-drugs-outwit-new-coronavirus.

[72]	Mak E . Gilead’s remdesivir enters China phase III trial to fight coronavirus. [2020-02-04].https://www.bioworld.com/articles/432804-gileads-remdesivir-enters-china-phase-iii-trial-to-fight-coronavirus?from=timeline.

[73]	Li Y, Zhang J Y, Wang N , et al. Therapeutic Drugs Targeting 2019 -nCoV Main Protease by High-Throughput Screening. bioRxiv. [2020-01-29]. doi: https://doi.org/10.1101/2020.01.28.922922. doi: https://doi.org/10.1101/2020.01.28.922922

[74]	Chen Y W, Yiu C P, Wong K Y . Prediction of the 2019 -nCoV 3C-like Protease (3CLpro) Structure: Virtual Screening Reveals Velpatasvir, Ledipasvir, and Other Drug Repurposing Candidates. ChemRxiv. [2020-02-11]. https://chemrxiv.org/articles/Prediction_of_the_2019-nCoV_3C-like_Protease_3CLpro_Structure_Virtual_Screening_Reveals_Velpatasvir_Ledipasvir_and_Other_Drug_Repurposing_Candidates/11831103.

[75]	Zhang J S, Ma X C, Yu F , et al. Teicoplanin potently blocks the cell entry of 2019 -nCoV. bioRxiv. [2020-02-13]. doi: https://doi.org/10.1101/2020.02.05.935387. doi: https://doi.org/10.1101/2020.02.05.935387

[76]	Contini A . Virtual Screening of an FDA Approved Drugs Database on Two COVID-19 Coronavirus Proteins. bioRxiv. [2020-02-13]. https://chemrxiv.org/articles/Virtual_Screening_of_an_FDA_Approved_Drugs_Database_on_Two_COVID-19_Coronavirus_Proteins/11847381.

[77]	李辉, 王业明, 徐九洋 , 等. 2019新型冠状病毒抗病毒治疗有药可期. 中华结核和呼吸杂志, 2020,43(00):E002-E002. DOI: 10.3760/cma.j.issn.1001-0939.2020.0002. doi: 10.3760/cma.j.issn.1001-0939.2020.0002

[77]	Li H, Wang Y M, Xu J Y , et al. Potential antiviral therapeutics for 2019 Novel Coronavirus. Chin J Tuberc Respir Dis, 2020,43(00):E002-E002. DOI: 10.3760/cma.j.issn.1001-0939.2020.0002. doi: 10.3760/cma.j.issn.1001-0939.2020.0002

[78]	NIAID. Coronavirus Vaccine Candidate Eyed for Human Trials by April (1). [2020-01-22]. https://news.bloomberglaw.com/pharma-and-life-sciences/coronavirus-vaccine-candidate-eyed-for-human-trials-by-april.

[79]	Vir Biotechnology. Vir Biotechnology applying multiple platforms to address public health risk from Wuhan coronavirus. [2020-01-22]. https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-applying-multiple-platforms-address-public.

[80]	The University of Queensland. Race to develop coronavirus vaccine.[2020-01-24]. https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine.

[81]	Inovio. Inovio Selected by CEPI to Develop Vaccine Against New Coronavirus. [2020-01-23]. http://ir.inovio.com/news-and-media/news/press-release-details/2020/Inovio-Selected-by-CEPI-to-Develop-Vaccine-Against-New-Coronavirus/default.aspx.

[82]	同济大学附属东方医院. 新型冠状病毒mRNA疫苗研发正在进行. [2020-01-28]. http://www.easthospital.cn/ArticleDetail?CombId=1F2D532B-515C-4AA0-9A0C-2DE0E20B7FA8,1F2D532B-515C-4AA0-9A0C-2DE0E20B7FA8,d3c74aa7-39a5-4f62-8b49-8b78e54fc16d.

[83]	Sarkar B, Ullah A, Johora F T , et al. The Essential Facts of Wuhan Novel Coronavirus Outbreak in China and Epitope-based Vaccine Designing against 2019 -nCoV. bioRxiv. [2020-02-11]. doi: https://doi.org/10.1101/2020.02.05.935072. doi: https://doi.org/10.1101/2020.02.05.935072

[84]	Abdelmageed M I, Abdelmoneim A H, Mustafa M I , et al. Design of multi epitope-based peptide vaccine against E protein of human 2019 -nCoV: An immunoinformatics approach. bioRxiv. [2020-02-11]. doi: https://doi.org/10.1101/2020.02.04.934232. doi: https://doi.org/10.1101/2020.02.04.934232

[85]	Tian X L, Li C, Huang A L, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. [2020-01-28]. doi: https://doi.org/10.1101/2020.01.28.923011. doi: https://doi.org/10.1101/2020.01.28.923011

[86]	Zhu J, Kin J, Xiao X , et al. Profiling the immune vulnerability landscape of the 2019 Novel Coronavirus. bioRxiv. [2020-02-12]. doi: https://doi.org/10.1101/2020.02.08.939553. doi: https://doi.org/10.1101/2020.02.08.939553

[87]	Huang C, Wang Y, Li X , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020,395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. doi: 10.1016/S0140-6736(20)30183-5

[88]	Chen N, Zhou M, Dong X , et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020,395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. doi: 10.1016/S0140-6736(20)30211-7

[89]	Rothe C, Schunk M, Sothmann P , et al. Transmission of 2019 -nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med. [2020-01-30]. doi: 10.1056/NEJMc2001468. doi: 10.1056/NEJMc2001468

[90]	Kupferschmidt K . Study claiming new coronavirus can be transmitted by people without symptoms was flawed. [2020-02-03]. https://www.sciencemag.org/news/2020/02/paper-non-symptomatic-patient-transmitting-coronavirus-wrong.

[91]	Holshue ML, DeBolt C, Lindquist S , et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. [2020-01-31]. doi: 10.1056/NEJMoa2001191. doi: 10.1056/NEJMoa2001191

[92]	Wang D, Hu B, Hu C , et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. [2020-02-07]. doi: 10.1001/jama.2020.1585. doi: 10.1001/jama.2020.1585

[93]	Wu Z, McGoogan J M . Characteristics of and Important Lessons From the Coronavirus Disease 201 (COVID-19) Outbreak in China: Summary of a Report of 72?314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. [2020-02-24]. doi: 10.1001/jama.2020.2648. doi: 10.1001/jama.2020.2648

[94]	Li Q, Guan X, Wu P , et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. [2020-01-29]. doi: 10.1056/NEJMoa2001316. doi: 10.1056/NEJMoa2001316

[95]	Wu JT, Leung K, Leung GM . Nowcasting and forecasting the potential domestic and international spread of the 2019 -nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020; S0140-6736(20) 30260-9. doi: 10.1016/S0140-6736(20)30260-9. doi: 10.1016/S0140-6736(20)30260-9

[96]	Chan JF, Yuan S, Kok KH , et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020,395(10223):514-523. doi: 10.1016/S0140-6736(20)30154-9. doi: 10.1016/S0140-6736(20)30154-9

[97]	Liu T, Hu J X, Kang M , et al. Transmission dynamics of 2019 novel coronavirus (2019-nCoV). bioRxiv. [2020-01-26]. doi: https://doi.org/10.1101/2020.01.25.919787. doi: https://doi.org/10.1101/2020.01.25.919787

[98]	Jung S, Akhmetzhanov A R, Hayashi K , et al. Real time estimation of the risk of death from novel coronavirus (2019 -nCoV) infection: Inference using exported cases. medRxiv. [2020-02-17]. doi: https://doi.org/10.1101/2020.01.29.20019547. doi: https://doi.org/10.1101/2020.01.29.20019547

[99]	Shao P, Shan Y G . Beware of asymptomatic transmission: Study on 2019 -nCoV prevention and control measures based on extended SEIR model. bioRxiv. [2020-01-28]. doi: https://doi.org/10.1101/2020.01.28.923169. doi: https://doi.org/10.1101/2020.01.28.923169

[100]	Kucharski A J, Russell T W, Diamond C , et al. Early dynamics of transmission and control of 2019 -nCoV: a mathematical modelling study. medRxiv. doi: https://doi.org/10.1101/2020.01.31.20019901. doi: https://doi.org/10.1101/2020.01.31.20019901

[101]	Read J M, Bridgen J R, Cummings D A , et al. Novel coronavirus 2019 -nCoV: early estimation of epidemiological parameters and epidemic predictions. medRxiv. [2020-01-28]. doi: https://doi.org/10.1101/2020.01.23.20018549. doi: https://doi.org/10.1101/2020.01.23.20018549

[102]	Tian H Y, Liu Y H, Li Y D , et al. Early evaluation of the Wuhan City travel restrictions in response to the 2019 novel coronavirus outbreak. medRxiv. [2020-02-18]. doi: https://doi.org/10.1101/2020.01.30.20019844. doi: https://doi.org/10.1101/2020.01.30.20019844

[103]	Shen M W, Peng Z H, Xiao Y N , et al. Modelling the epidemic trend of the 2019 novel coronavirus outbreak in China. bioRxiv. [2020-01-25]. doi: https://doi.org/10.1101/2020.01.23.916726. doi: https://doi.org/10.1101/2020.01.23.916726

[104]	Ming W K, Huang J, Zhang C L . Breaking down of the healthcare system: Mathematical modelling for controlling the novel coronavirus(2019-nCoV) outbreak in Wuhan, China. bioRxiv. [2020-01-28]. doi: https://doi.org/10.1101/2020.01.27.922443. doi: https://doi.org/10.1101/2020.01.27.922443

[105]	Zhang C, Wang M . MRCA time and epidemic dynamics of the 2019 novel coronavirus. bioRxiv. [2020-01-31]. doi: https://doi.org/10.1101/2020.01.25.919688. doi: https://doi.org/10.1101/2020.01.25.919688

[106]	Xiong C L, Jiang L F, Chen Y , et al. Evolution and variation of 2019 -novel coronavirus. bioRxiv. [2020-01-30]. doi: https://doi.org/10.1101/2020.01.30.926477. doi: https://doi.org/10.1101/2020.01.30.926477

[107]	ParK S W, Bolker B M, Champredon D , et al. Reconciling early-outbreak estimates of the basic reproductive number and its uncertainty: a new framework and applications to the novel coronavirus(2019-nCoV) outbreak. medRxiv. [2020-02-07]. doi: https://doi.org/10.1101/2020.01.30.20019877. doi: https://doi.org/10.1101/2020.01.30.20019877

[1]	YUN Tao,GONG Yue,GU Peng,XU Bing-bing,LI Jin,ZHAO Xi-chen. Present Situation and Prospect of International S&T Cooperation between China and Countries Participating in the “Belt and Road” Initiative to Combat COVID-19[J]. China Biotechnology, 2021, 41(7): 110-121.

[2]	XU Ye-chun,LIU Hong,LI Jian-feng,SHEN Jing-shan,JIANG Hua-liang. Recent Progress in Drug Development against COVID-19[J]. China Biotechnology, 2021, 41(6): 111-118.

[3]	FU Gui-e,LI Jin,GENG Pei-ran,SHEN Meng-qiu,ZHANG Jin-qian-nan,ZHAO Xi-chen. A Study on COVID-19 Prevention Force of Typical Cities in the Guangdong-Hong Kong-Macao Greater Bay Area Based on the Medical Perspective[J]. China Biotechnology, 2021, 41(12): 125-140.

[4]	WU Rui-jun,LI Zhi-fei,ZHANG Xin,PU Run,AO Yi,SUN Yan-rong. Development and Prospect of Antibody Drugs for SARS-CoV-2[J]. China Biotechnology, 2020, 40(5): 1-6.

[5]	XIE Hua-ling,LV Lu-cheng,YANG Yan-ping. Patent Analysis of Global Coronavirus Vaccine[J]. China Biotechnology, 2020, 40(1-2): 57-64.

[6]	LIN Fu-yu,LIU Jin-yi,CHENG Yong-qing. Progress of Interferon α1b Research and Clinical Use Against SARS-CoV-2[J]. China Biotechnology, 2020, 40(12): 1-7.

[7]	LIAO Xiao-yan,CHEN Li-li. The Progress in the Development of COVID-19 Vaccine[J]. China Biotechnology, 2020, 40(12): 8-17.

[8]	CHEN Li-jun,QU Jing-jing,XIANG Charlie. Therapeutic Potentials, Clinical Studies, and Application Prospects of Mesenchymal Stem Cells in 2019 Novel Coronavirus (COVID-19)[J]. China Biotechnology, 2020, 40(11): 43-55.

[9]	Zhi-yong XIE,Xiang ZHOU. Machine Learning in Medical Imaging:the Applications in Drug Discovery and Precision Medicine[J]. China Biotechnology, 2019, 39(2): 90-100.

Viewed

Full text

Abstract

Cited

Shared

Discussed